Document Detail

Synthesis and evaluation of antiinflammatory, analgesic and ulcerogenic potential of NSAIDs bearing 1,3,4-oxadiazole scaffold.
Jump to Full Text
MedLine Citation:
PMID:  23112397     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Synthesis of 1,3,4-oxadiazole derivatives of diclofenac and mefenamic acid are described. The target compounds 5-[2-(2,6-dichloroanilino)benzyl]-2-aryl-1,3,4-oxadiazole (3a-3e) and 5-[2-(2,3-dimethylanilino)phenyl]-2-(aryl)-1,3,4-oxadiazole (6a-6e) were obtained by treating 2 and 5 with various aromatic acids using POCl(3) as dehydrating agent. They were purified and characterized by IR, (1)H-NMR and elemental analysis. These compounds were further subjected to antiinflammatory, analgesic and acute ulcerogenic activity. Compound 3c and 6d exhibited good antiinflammatory activity and compounds 3c, 3e, 6c, 6d, 6e were found to be non ulcerogenic.
Authors:
R R Somani; U V Bhanushali
Related Documents :
21790197 - Reaction of o2 with [(-)-sparteine]pd(h)cl: evidence for an intramolecular [h-l]+ "redu...
21950347 - Biochemical insight into physiological effects of h2s: reaction with peroxynitrite and ...
21845097 - Variations of antioxidant properties and no scavenging abilities during fermentation of...
23376247 - Synthesis and biological evaluation of thieno [2',3':4,5]pyrimido[1,2-b][1,2,4]triazine...
23467917 - Synthesis of novel spirooxindolo-pyrrolidines, pyrrolizidines, and pyrrolothiazoles via...
17701557 - Effect of 2,3,5,4'-tetrahydroxystilbene-2-o-beta-d-glucoside on lipoprotein oxidation a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Indian journal of pharmaceutical sciences     Volume:  73     ISSN:  1998-3743     ISO Abbreviation:  Indian J Pharm Sci     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2012-10-31     Completed Date:  2012-11-01     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  7809431     Medline TA:  Indian J Pharm Sci     Country:  India    
Other Details:
Languages:  eng     Pagination:  634-40     Citation Subset:  -    
Affiliation:
Department of Pharmaceutical Chemistry, VES's College of Pharmacy, Collector Colony, Chembur, Mumbai, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Indian J Pharm Sci
Journal ID (iso-abbrev): Indian J Pharm Sci
Journal ID (publisher-id): IJPhS
ISSN: 0250-474X
ISSN: 1998-3743
Publisher: Medknow Publications & Media Pvt Ltd, India
Article Information
Copyright: © Indian Journal of Pharmaceutical Sciences
open-access:
Received Day: 04 Month: 4 Year: 2011
Revision Received Day: 30 Month: 11 Year: 2011
Accepted Day: 03 Month: 12 Year: 2011
Print publication date: Season: Nov-Dec Year: 2011
Volume: 73 Issue: 6
First Page: 634 Last Page: 640
PubMed Id: 23112397
ID: 3480748
Publisher Id: IJPhS-73-634
DOI: 10.4103/0250-474X.100237

Synthesis and Evaluation of Antiinflammatory, Analgesic and Ulcerogenic Potential of NSAIDs Bearing 1,3,4-Oxadiazole Scaffold
R. R. Somaniaff1*
U. V. Bhanushali1
Department of Pharmaceutical Chemistry, VES's College of Pharmacy, Collector Colony, Chembur, Mumbai, India
1Department of Pharmaceutical Chemistry, Bharati Vidyapeeth's College of Pharmacy, Sector 8, C.B.D., Navi Mumbai–400 614, India
*Address for correspondence:rakeshrsomani@gmail.com

Non steroidal antiinflammatory drugs (NSAIDs) are the first line drugs for the treatment of arthritis, pain and inflammatory disorder[1]. The pharmacological activity of NSAIDs is related to the suppression of prostaglandin biosynthesis from arachidonic acid by inhibiting the enzyme prostaglandin endoperoxidase, popularly known as cyclooxygenase (COX)[2, 3]. It was reported that COX exists in two isoforms, COX- 1 and COX-2, which are regulated and expressed differently[46]. COX-1 provides cytoprotection in the gastrointestinal tract (GIT), whereas inducible COX-2 selectively mediates inflammatory signals[79]. Since most of the currently available NSAIDs in the market show greater selectivity for COX-1 than COX-2[10], chronic use of NSAIDs, including diclofenac and mefenamic acid, may elicit appreciable GI irritation, bleeding and ulceration[11]. GI damage from NSAID is generally attributed to two factors, local irritation by the direct contact of carboxylic acid (–COOH) moiety of NSAIDs with GI mucosal cells (topical effect) and decreased tissue prostaglandin production in tissues which undermines the physiological role of cytoprotective prostaglandins in maintaining GI health and homoeostasis are the effects shown by the nonselective COX inhibitors[12]. The ulerogenesis due to carboxylate group can be minimized by modifying the acid functionality to ester[13], amide or NO releasing group[14, 15]. Also derivatisation of the carboxylic acid group of NSAIDs to various five member heterocycles has been reported to retained antiinflammatory activity with reduced ulcerogenic potential[1619].

Among the various heterocycles, oxadiazole, especially 2,5-disubstituted-1,3,4-oxadiazole has unique features associated with it. It consists of toxophoric moiety (N-C-O)[20] which enhances its potential as an effective biodynamic molecule, additionally the oxadiazole ring has been reported to be weak acidic in nature and it is an isoster for the ester functionality[21]. The 2,5-disubstituted-1,3,4-oxadiazole is associated with diverse biological activities like anticonvulsant[22], antidepressant[23], non-ulcerogenic antiinflammatory[24], anticancer[25], antimicrobial-antiTB[26] and antiangiogenic[27] etc, which makes it biologically important scaffold.

Thus in our attempt to find new, safer and potent antiinflammatory agent and our continued interest in oxadiazole chemistry[2833], we built oxadiazole nucleus on the two most popular NSAIDs diclofenac and mefenamic acid and evaluated them for their antiinflammatory, analgesic and ulcerogenic activities.


MATERIALS AND METHODS

All the chemicals were obtained from commercial suppliers and used without further purification. All the melting points were determined on ‘Veego’ VMP-D apparatus and are uncorrected. Silica gel G plates of 3x8 cm (Sigma-Aldrich) were used for TLC and spots were located by UV or in iodine chamber. The IR spectra were recorded in the 4000-400 cm-1 range using KBr discs on FT-IR 8400 Shimadzu spectrometer. 1H NMR spectra were recorded on Varian Mercury (300 MHz) spectrometer in CDCl3 with TMS as an internal standard and values are expressed in ppm. Elemental analyses were performed for C, H, N and were found within ±0.4% of theoretical values.

Synthesis of methyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate (1) and methyl 2-[(2,3- dimethylphenyl)amino]benzoate (4):

In a solution of acids (diclofenac and mefenamic acid) (0.033 moles, 10 g) with absolute methanol (50 ml), was added 5 ml of conc. H2SO4 under stirring. It was then refluxed for 6-7 h on water bath, cooled and concentrated under reduced pressure. The residue was poured onto crushed ice and neutralized with 10% NaHCO3 solution to yield solid precipitate. The solid was collected by filtration, washed twice with ice cold water and dried[34].

Synthesis of of 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetohydrazide (2) and 2-[(2,3- dimethylphenyl)amino]benzohydrazide (5):

To a solution of 1 (0.05 moles, 15.5 g), in absolute methanol (40 ml), 3.75 g of hydrazine hydrate (0.075 moles) was added and the reaction mixture was reflux for 15 h. It was then concentrated, cooled and poured onto ice cold water. The white solid thus separated out was filtered, dried and recrystallised from absolute ethanol[35].

Synthesis of 5-[2-(2,6-dichloroanilino)benzyl]-2-aryl-1,3,4-oxadiazole (3a-3e) and 5- [2-(2,3- dimethylanilino)phenyl]-2-(aryl)-1,3,4-oxadiazole (6a-6e):

The mixture of 2 or 5 (1 g, 0.01 mole) and various aromatic acid (0.01 mole) was dissolved in 3-5 ml of phosphorus oxychloride (POCl3). The reaction mixture was heated under reflux for 4 h. After completion of the reaction, (monitored by TLC, ethyl acetate:hexane:: 0.5:1.5) mixture was neutralized with ice cold solution of 10% NaHCO3. The precipitate thus obtained was filtered, washed with ice cold water and purified by column chromatography[36] (ethyl acetate:hexane:: 0.5:1.5).

5-[2-(2,6-Dichloroanilino) benzyl]-2-(phenyl)-1,3,4-oxadiazole (3a): Yield 71%, white crystalline solid, m.p. 80-82°, 1H NMR (CDCl3): δ 7.60-7.50 (m, 5H, Ar-H), 7.42 (d, 2H, Ar-H), 7.20-7.10 (m, 4H, Ar-H), 6.80-6.70 (t, 1H, Ar-H), 6.60 (s, 1H, NH), 1.55 (s, 2H, CH2). IR (KBr, cm-1): 3254, (NH), 3072 (Ar CH), 1606(C=N), 1101, 1000, 902(C-O-C). Rf; 0.84.

5-{[2-(2,6-Dichloroanilino)benzyl]-2-(3-chlorphenyl)}-1,3,4-oxadiazole (3b): Yield 72%, whitish yellow solid, m.p. 83-84°, 1H NMR (CDCl3): δ 7.60-7.50 (m, 4H, Ar-H), 7.48-7.40 (m, 3H, Ar-H), 7.30-7.10 (m, 3H, Ar-H), 6.80-6.70 (t, 1H, Ar-H), 6.68 (s, 1H, NH), 1.54 (s, 2H, CH2). IR (KBr, cm-1): 3252, (NH), 2953 (Ar CH), 1604(C=N), 1101, 1096 (C-O-C). Rf; 0.78.

5-{[2-(2,6-Dichloroanilino)benzyl]-2-(4-methylphenyl)}-1,3,4-oxadiazole (3c): Yield 79%, pinkish white solid, m.p. 79-80°, 1H NMR (CDCl3): δ 7.60-7.50 (m, 4H, Ar-H), 7.40 (d, 2H, Ar-H), 7.20-7.10 (d, 2H, Ar-H), 7.00 (d, 2H, Ar-H), 6.80-6.70 (t, 1H, Ar-H), 6.68 (s, 1H, NH), 1.50 (s, 2H, CH2), 1.26 (s, 3H, CH3). IR (KBr, cm-1): 3126, (NH), 2923 (Ar CH), 1589(C=N), 1101, 1090 (C-O-C). Rf; 0.81.

5-{[2-(2,6-Dichloroanilino)benzyl]-2-(pyridine-4-yl)}-1,3,4-oxadiazole (3d): Yield 74 %, white solid, m.p. 82-84°, 1H NMR (CDCl3): δ 7.60-7.50 (d, 2H, Ar-H), 7.52-7.40 (m, 4H, Ar-H), 7.30-7.20 (d, 2H, Ar-H), 7.10 (d, 2H, Ar-H), 6.81-6.70 (d, 2H, Ar-H), 6.68 (s, 1H, NH), 1.50 (s, 2H, CH2). IR (KBr, cm-1): 3326 (NH), 2929 (Ar CH), 1614 (C=N), 1172, 1092, 1022 (C-O-C). Rf; 0.79.

5-{[2-(2,6-Dichloroanilino)benzyl]-2-(1-naphthyl)}-1,3,4-oxadiazole (3e): Yield 80%, white crystalline solid, m.p. 88-90°, IR (KBr, cm -1): 3128 (NH), 3028 (Ar CH), 1588 (C=N), 1103, 1010, 998 (C-O-C). Anal. Calcd for C25H17Cl2N3O: C, 68.18; H, 3.86; N, 9.54. Found C,68.11; H, 3.82; N, 9.55%. Rf; 0.80.

5-[2-(2,3-Dimethylanilino)phenyl]-2-(phenyl)-1,3,4-oxadiazole (6a): Yield 63%, yellow amorphous solid, m.p. 117-119°, IR (KBr, cm-1): 3276 (NH), 2921 (Ar CH), 1622 (C=N), 1103, 1165, 1010 (C-O-C). Calcd for C22H19N3O: % C, 77.41; H, 5.57; N, 12.31. Found % C, 77.32; H, 5.50; N, 12.01. Rf; 0.80.

5-[2-(2,3-Dimethylanilino)phenyl]-2-(3-chlorophenyl)-1,3,4-oxadiazole (6b): Yield 70%, yellow amorphous solid, m.p. 117-118°, IR (KBr, cm-1): 3211 (NH), 2921 (Ar CH), 1596 (C=N), 1157, 1089, 977 (C-O-C). Calcd for C22H18ClN3O: % C, 67.64; H, 4.79; N, 11.18. Found %C, 67.43; H, 4.83; N, 11.00.Rf; 0.86.

5-[2-(2,3-Dimethylanilino) phenyl]-2-(4-methylphenyl)-1,3,4-oxadiazole (6c): Yield 65%, yellow amorphous solid, m.p. 121-123°, 1H NMR (CDCl3): δ 8.30-8.20 (m, 4H, Ar- H), 7.95 (d, 2H, Ar- H), 7.90-7.80 (m, 3H, Ar- H), 7.42 (d, 2H, Ar- H), 7.23 (s,1H, NH), 2.95 (s, 3H, CH3), 2.60 (s, 3H, CH3), 1.56 (s, 3H, CH3). IR (KBr, cm -1): 3326 (NH), 2927 (Ar CH), 1627 (C=N), 1184, 1087, 1049 (C-O-C). Rf; 0.78.

5-[2-(2,3-Dimethylanilino)phenyl]-2-(pyridine-4-yl)-1,3,4-oxadiazole (6d): Yield 62%, yellow amorphous solid, m.p. 115-116°, 1H NMR (CDCl3): δ 8.42 (d, 2H, Ar- H), 8.30-8.20 (d, 2H, Ar- H), 7.86-7.76 (m, 3H, Ar- H), 7.42 (d, 2H, Ar- H), 7.22 (s,1H, NH), 2.90 (s, 3H, CH3), 2.60 (s, 3H, CH3). IR (KBr, cm-1): 3147 (NH), 2950 (Ar CH), 1608 (C=N), 1186, 1060, 986 (C-O-C). Rf; 0.81.

5-[2-(2,3-Dimethylanilino)phenyl]-2-(1-naphthyl)-1,3,4-oxadiazole (6e): Yield 74%, yellow solid, m.p. 113-115°, 1H NMR (CDCl3): δ 8.20-8.10 (m 4H, Ar- H), 8.00-7.90 (m, 4H, Ar- H), 7.86-7.76 (m, 3H, Ar- H), 7.60-7.50 (m, 3H, Ar- H), 7.20 (s,1H, NH), 2.90 (s, 3H, CH3), 2.60 (s, 3H, CH3). IR (KBr, cm-1): 3332, (NH), 2929 (Ar CH), 1627 (C=N), 1159, 1089 (C-O-C). Rf; 0.77.

Acute toxicity study:

The acute toxicity study was performed as per literature method[37] on female swiss albino mice, weighing 20-25 g. Animals were kept overnight fasting (about 18 h) before administering the doses. Graded doses of compounds (175 mg/kg to 1750 mg/kg) were administered orally. Animals were observed for mortality at least once during the first 30 min, periodically during the first 24 h (with special attention given during the first 4 h) and daily thereafter, for a total of 14 days, except where they needed to be removed from the study and humanely killed for animal welfare reasons or were found dead.

Antiinflammatory activity:

This activity was performed as per the literature method[38] on groups of six sprague dawley rats weighing 150-180 g each. A freshly prepared suspension of carrageenan (1.0% w/v, 0.1 ml) was injected in the planter region of right hind paw of each rat one hour after treating them with 10 mg/kg of test compounds. One group was treated as control and the animals of the other groups were pretreated with the test compounds suspended in 1.0% CMC with few drops of tween 80 given orally 1 h before the carrageenan treatment. The paw volume was measured after 1, 3 and 24 h of carrageenan treatment with the help of pleythysmometer. The percent antiinflammatory activity was calculated according to the formula: % Antiinflammatory activity = (Vc – Vt/Vc) × 100, where, Vt represents the mean increase in paw volume in rats treated with test compounds, Vc represents the mean increase in paw volume in control group of rats.

Analgesic activity:

The acetic acid-induced writhing test[39] was performed for measure analgesic activity by an i.p. injection of 1% aqueous acetic acid solution in a volume of 0.1 ml. Each group of six albino mice was kept. Mice were kept individually in the test cage, before acetic acid injection and habituated for 30 min. Analgesic activity was tested after p.o. administration of test drugs at the dose of 10 mg/kg. All compounds were suspended in 1% CMC solution with few drops of tween 80. One group was kept as control and received p.o. administration of 1% CMC. After 1 h of administration of test compounds, 0.10 ml of 1% acetic acid solution was given to mice intraperitoneally. Stretching movements consisting of arching of the back, elongation of body and extension of hind limbs were counted for 5–15 min of acetic acid injection. The analgesic activity was expressed in terms of % pain inhibition. % Analgesic activity = (n–n/n)×100 Where n = mean number of writhes of control group and n = mean number of writhes of test group.

Acute ulcerogenesis:

Acute ulcerogenesis test was done according to literature method[40]. Albino rats have been divided into different groups consisting of six animals in each group. Ulcerogenic activity was evaluated after p.o. administration of test compounds or standard at the dose of 30 mg/kg. Control rats received p.o. administration of vehicle (suspension of 1% carboxy methyl cellulose). Food but not water was removed 24 h before administration of the test compounds. After the drug treatment, the rats were fed normal diet for 17 h and then sacrificed. The stomach was removed and opened along the greater curvature, washed with distilled water and cleaned gently by dipping in saline. The mucosal damage was examined by means of a magnifying glass. For each stomach, the mucosal damage was assessed according to the following scoring system: 0.0 score was given to normal stomach (no injury, bleeding and latent injury). 0.5 score was to latent injury or widespread bleeding (>2 mm). 1.0 was to slight injury (2–3 dotted lines), 2.0 for severe injury (continuous lined injury or 5–6 dotted injuries). 3.0 to very severe injury (several continuous lined injuries) and 4.0 for widespread lined injury or widened injury. The mean score of each treated group minus the mean score of control group was regarded as severity index of gastric mucosal damage.

Data are expressed as mean±S.E.M; Data analyzed by one way ANOVA followed by Dunnett's test, significance of the difference between the control group and rats treated with the test compounds. The difference in results was considered significant when P<0.01.


RESULTS AND DISCUSSION

The present study was aimed to replace the carboxylate functionality of diclofenac and mefenamic acid with less acidic 1,3,4-oxadiazole nucleus to protect the gastric mucosa from free carboxylate moiety. Five oxadiazole derivatives of diclofenac and mefenamic acid were synthesized as out line in scheme (fig. 1). The titled compounds 3a-3j and 6a-6j were obtained by reacting 2 and 5 respectively with various aromatic acids in the presence of POCl3 as cyclodehydrating agent. Subsequent purification by column chromatography using ethyl acetate: hexane as a mobile phase and silica as a stationary phase yielded final compounds in moderate to higher yields. They were characterized by the IR (KBr) as sharp bands were observed around 3254 cm-1 (NH stretch), 3056 cm-1 (aromatic C-H stretch), 1608 cm-1 (C=N), 1068-1020 cm-1 (C-O-C stretch of oxadiazole ring) and their structures were further confirmed by 1H NMR and elemental analysis.

The titled compounds were subjected to pharmacological evaluation which includes acute oral toxicity study, antiinflammatory, analgesic and acute ulcerogenic activities. The toxicity studies revealed that all compounds exhibited LD50 values of 1750 mg/kg which is greater than the LD50 of the diclofenac (95 to 1300 mg/kg)[41] and mefenamic acid (525 mg/kg)[42]. The antiinflammatory activity of the synthesized compounds (3a-3e and 6a-6e) showed that all of these compounds were sufficiently active in inhibiting the inflammation. However compound 3c and 6d exhibited percent inflammation inhibitions of 82.61% and 79.50% (Table 1 and fig. 2). The analgesic activity of the compounds (3a-3e and 6a-6e) was studied by using acetic acid induced writhing test in mice. The results of acetic acid induced writhing test showed that all compounds possess significant analgesic activity as compared with the control group (Table 2 and fig. 3). Ulcerogenic effect of most active oxadiazole erivatives of diclofenac (3c, 3e) and mefenamic acid (6c, 6d, 6e) was evaluated for gastric ulcerogenic potential in rat stress model at 3 times the therapeutic doses. When compared with standard, these compounds showed less ulceration than the standard drugs. The results are shown in (Table 3 and fig. 4).

In summary, we disclosed that the effects of replacement of carboxylate functionality of the two most popular NSAIDs, diclofenac and mefenamic acid with 1,3,4-oxadiazole scaffold, with the objective of developing better antiinflammatory profile with minimum ulcerogenic activity and safety profile. The oxadiazole ring being weak acidic in nature and isoster for ester functionality, reduces the ulcerogenicity of the diclofenac and mefenamic acid and retain its antiinflammatory potential. However replacement with oxadiazole scaffold did not improve the analgesic activity of these molecules.


Notes

Somani and Bhanushali: Nonulcerogenic 1,3,4-oxadiazole Derivatives of Diclofenac and Mefenamic Acid

REFERENCES
1. Talley JJ,Brown DL,Carter JS. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2J Med ChemYear: 200043775710715145
2. Smith CJ,Zhang Y,Koboldt CM. Pharmacological analysis of cyclooxygenase-1 in inflammationProc Natl Acad Sci USAYear: 1998951331389789085
3. Warner TD,Giuliano F,Vaynovie I,Bukasa A,Mitchell JA,Vave JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysisProc Natl Acad Sci USAYear: 1999965638
4. Marnett LJ,Kalgutkar AS. Cyclooxygenase 2 inhibitors: discovery, selectivity and the futureTrends Pharmacol SciYear: 199920465910542447
5. Dannhardt G,Kiefer W. Cyclooxygenase inhibitors-current status and future prospectsEur J Med ChemYear: 2001361092611311743
6. Marnett LJ,Kalgutkar AS. Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic antiinflammatory agentsCurr Opin Chem BiolYear: 19982482909736921
7. Parsit P,Reindeau D. Selective Cyclooxygenase-2 InhibitorsAnnu Rep Med ChemYear: 19973221120
8. Habeeb AG,Rao P,Knaus ED. Design and Synthesis of 4,5-Diphenyl-4-isoxazolines: Novel Inhibitors of Cyclooxygenase-2 with Analgesic and Antiinflammatory ActivityJ Med ChemYear: 2001442921711520200
9. Almansa C,Alfon J,Cavalcanti FL. Synthesis and Structure–Activity Relationship of a New Series of COX-2 Selective Inhibitors: 1,5-DiarylimidazolesJ Med ChemYear: 20034634637512877584
10. Jackson LM,Hawkey CJ. Gastrointestinal effects of COX-2 inhibitorsExp Opin Invest DrugsYear: 1999896371
11. Allison MC,Howatson AG,Torrance CJ,Lee FD,Russell IG. Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory DrugsN Engl J MedYear: 1992327749541501650
12. Hawkey C,Laine L,Simon T,Beaulieu AA,Maldonado A. Comparison of the Effect of Rofecoxib (a Cyclooxygenase 2 Inhibitor), Ibuprofen, and Placebo on the Gastroduodenal Mucosa of Patients with Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled TrialArthritis RheumYear: 200043370710693877
13. Mohan R,Ramaa CS. Ester prodrugs of flurbiprofen: Synthesis, plasma hydrolysis and gastrointestinal toxicityIndian J ChemYear: 200746B11648
14. Ziakas GN,Rekka EA,Gavalas AM,Eleftheriou PT,Tsiakitzis KC,Kourounakis PN. Nitric oxide releasing derivatives of tolfenamic acid with anti-inflammatory activity and safe gastrointestinal profileBioorg Med ChemYear: 20051364859216185877
15. Galanakis D,Kourounakis A,Doulgkeris C,Rekka E. Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicityBioorg Med Chem LettYear: 20041436394315203134
16. Kalgutkar AS,Marnett AB,Crews BC,Remmel RP,Marnett LJ. Ester and Amide Derivatives of the Nonsteroidal Anti-inflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 InhibitorsJ Med ChemYear: 20004328607010956194
17. Duflos M,Nourrisson MR,Brelet J,Courant J,Le BJ,Grimaud GN,et al. N-Pyridinyl-indole-3-(alkyl) carboxamides and derivatives as potential systemic and topical inflammation inhibitorsEur J Med ChemYear: 2001365455311525845
18. Kalgutkar AS,Crews BC,Rowlinson SW,Garner C,Seibert K,Marnett LJ. Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2ScienceYear: 19982801268709596581
19. Bhandari SV,Bothara KJ. Design, Synthesis and Evaluation of Antiinflammatory, Analgesic and Ulcerogenicity studies of Novel S-Substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of Diclofenac acid as Nonulcerogenic DerivativesBioorg Med ChemYear: 20081618223118248993
20. Hashimoto M,Ohta H. Studies on Meso-ionic Compounds. XIII). Reaction between Acetic Anhydride and Azoles having Carboxymethylmercapto-groupBull Chem Soc JapanYear: 19609313949
21. Hughes TV,Wetter SK,Connolly PJ. A novel 5-[1,3,4-oxadiazol-2- yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activityBioorg Med Chem LettYear: 2008188969
22. Zarghi A,Faizi M,Shafaghi B,Ahadian A. Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazolesBioorg Med Chem LettYear: 2005151863515780622
23. Zarghi A,Faizi M,Shafaghi B,Ahadian A. Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazolesas benzodiazepine receptor agonistsBioorg Med Chem LettYear: 2005153126915876530
24. Bhandari SV,Parikh JK,Bothara KG. Design, synthesis, and evaluation of anti-inflammatory, analgesic, ulcerogenicity, and nitric oxide releasing studies of novel indomethacin analogs as nonulcerogenic derivativesJ Enzym Inhib Med ChemYear: 20102552030
25. Holla SB,Poojary NK,Bhat SK. Synthesis and anticancer studies on some 2- chloro-1,4-bis-(5-substituted-1,3,4-oxadazol-2ylmetheleneoxy)phenylene derivativesIndian J ChemYear: 200544B166973
26. Kumar GV Suresh,Rajendraprasad Y,Mallikarjuna BP,Chandrashekar SM,Kistayya C. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agentsEur J Med ChemYear: 20104520637420149496
27. Kumar A,D’Souza SS,Gaonkar SL,Lokanatha Rai KM. Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1α in Ehrlich ascites tumor cellsCancer Chemother PharmacolYear: 20096412213319370348
28. Somani R,Shirodkar P,Kadam V. Synthesis and Antibacterial Activity of Some New 2,5-Disubstituted-1,3,4-oxadiazole DerivativesChin J ChemYear: 200826172731
29. Pal T,Somani RR,Shirodkar PY,Bhanushali UV. Quantitative structure activity relationship (QSAR) studies of a series of 2,5-disubstituted-1,3,4-oxadiazole derivatives as biologically potential compoundsMed Chem ResYear: 20112015505
30. Somani R,Shirodkar P. Synthesis, Antibacterial and Antitubercular Evaluation of Some 1,3,4-Oxadiazole AnaloguesAsian J ChemYear: 200820618994
31. Somani RR,Agrawal AG,Bhanushali UV,Kalantri PP,Clercq ED. Synthesis and Biological Evaluation of some 2,5-Disubstituted -1,3,4-Oxadiazole DerivativesInt J Drug Des DiscYear: 201124138
32. Somani R,Shirodkar P,Kadam V. Synthesis and Anticancer Evaluation of some Newer 2,5-Disubstituted-1,3,4-Oxadiazole AnaloguesLett Drug Des DiscoYear: 200853648
33. Somani R,Agrawal A,Kalantri P,Gavarkar P,Clercq ED. Investigation of 1,3,4-Oxadiazole Scaffold as Potentially Active CompoundsInt J Drug Design DiscYear: 2011235360
34. Sriram D,Yogeeswari P,Devakaram RV. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amidesBioorg Med ChemYear: 2006143113816412646
35. Amir M,Kumar S. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino) phenyl]acetic acid derivativesEur J Med ChemYear: 2004395354515183912
36. Venkatapuram P,Reddy GS,Mohan A,Konda M. Synthesis of symmetrical and unsymmetrical 1,3,4-oxadiazoles and their interconversion to 1,3,4-thiadiazoles and 1,2,4-triazolesARKIVOCYear: 2008xvii4860
37. OECD guideline for testing of chemicals, Acute oral toxicity, environmental Health and Safety Monograph Series on Testing and Adjustment No. 425Year: 2006127
38. Schleyerbach R,Weithmann KU,Bartlett RR. Vogel HGAnalgesic, anti-inflammatory, and anti-pyretic activityDrug Discovery and Evaluation; Pharmacological AssaysYear: 20022nd edBerlinSpringer-Verlag759
39. Schleyerbach R,Weithmann KU,Bartlett RR. Vogel HGAnalgesic, anti-inflammatory, and anti-pyretic activityDrug Discovery and Evaluation; Pharmacological AssaysYear: 20022nd edBerlinSpringer-Verlag716
40. Cioli V,Putzolu S,Rossi V,Corradino C. The role of direct tissue contact in the production of gastrointestinal ulcers by antiinflammatory drugs in ratsToxicol Appl PharmacolYear: 1979502839505458
41. The European Agency for evaluation of medicinal products (Veterinary Medicines and Inspections) cited in their report, Reference No, EMEA/MRL/885/03-FINAL, dated, September 2003
42. Material safety data sheet, Spectrum Laboratory Products INC, 14422 S. San Pedro Street Gardena, CA 90248

Figures

[Figure ID: F1]
Fig. 1 

Scheme of synthesis.



[Figure ID: F2]
Fig. 2 

Plot of mean paw volume (ml) after administration of compounds 3a-3e and 6a-6e.



[Figure ID: F3]
Fig. 3 

Plot of number of writhes after i. p. administration of 1% acetic acid solution to animal treated with compounds 3a-3e, 6a-6e and standards.



[Figure ID: F4]
Fig. 4 

Plot of mean ulcer sore of animal after the administration of test compounds.



Tables
[TableWrap ID: T1] TABLE 1 

MEAN % INFLAMMATION INHIBITION IN RATS AFTER ADMINISTRATION OF COMPOUNDS 3A-3E, 6A-6E AND STANDARDS



[TableWrap ID: T2] TABLE 2 

MEAN % PAIN INHIBITION AFTER TREATMENT WITH COMPOUNDS 3A-3E, 6A-6E AND STANDARDS



[TableWrap ID: T3] TABLE 3 

MEAN ULCER SORE AND ULCER INDEX AFTER ADMINISTRATION OF COMPOUNDS




Article Categories:
  • Research Paper

Keywords: Analgesic, antiinflammatory, diclofenac, mefenamic acid, ulcerogenic activity, 1,3,4-oxadiazole.

Previous Document:  Ranitidine Hydrochloride-loaded Ethyl Cellulose and Eudragit RS 100 Buoyant Microspheres: Effect of ...
Next Document:  Development and evaluation of microbial degradation dependent compression coated secnidazole tablets...